Sökning: onr:"swepub:oai:DiVA.org:uu-267596" > Pharmacokinetic Con...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 03441naa a2200433 4500 | |
001 | oai:DiVA.org:uu-267596 | |
003 | SwePub | |
008 | 151124s2016 | |||||||||||000 ||eng| | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-2675962 URI |
024 | 7 | a https://doi.org/10.1016/j.ejps.2016.07.0032 DOI |
040 | a (SwePub)uu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Lindqvist, Annika,d 1983-u Uppsala universitet,Institutionen för farmaceutisk biovetenskap,Translational PKPD4 aut0 (Swepub:uu)annbo297 |
245 | 1 0 | a Pharmacokinetic Considerations of Nanodelivery to the Brain :b Using Modeling and Simulations to Predict Outcome of Liposomal Formulations |
264 | 1 | b Elsevier BV,c 2016 |
338 | a print2 rdacarrier | |
520 | a The use of nanocarriers is an intriguing solution to increase the brain delivery of novel therapeutics. The aim of this paper was to use pharmacokinetic analysis and simulations to identify key factors that determine the effective drug concentration-time profile at the target site in the brain. Model building and simulations were based on experimental data obtained from the administration of the opioid peptide DAMGO in glutathione tagged PEGylated liposomes to rats. Different pharmacokinetic models were investigated to explore the mechanisms of increased brain delivery. Concentration time profiles for a set of formulations with varying compound and carrier characteristics were simulated. By controlling the release rate from the liposome, the time profile and the extent of brain delivery can be regulated. The modeling did not support a mechanism of the liposomes passing the brain endothelial cell membrane in an intact form through endocytosis or transcytosis. The most likely process was found to be fusion of the liposome with the endothelial luminal membrane. The simulations revealed that low permeable compounds, independent on efflux, will gain the most from a nanocarrier formulation. The present model based approach is useful to explore and predict possibilities and limitations of carrier-based systems to the brain. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Medicinska och farmaceutiska grundvetenskaperx Farmaceutiska vetenskaper0 (SwePub)301012 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Basic Medicinex Pharmaceutical Sciences0 (SwePub)301012 hsv//eng |
653 | a Liposomes | |
653 | a Nanocarriers | |
653 | a Brain delivery | |
653 | a Pharmacokinetics | |
653 | a Active transport | |
653 | a Blood-brain barrier | |
653 | a Permeability | |
653 | a Release rate | |
653 | a Modeling and simulations | |
653 | a Farmakokinetik och läkemedelsterapi | |
653 | a Pharmacokinetics and Drug Therapy | |
700 | 1 | a Fridén, Markusu AstraZeneca R&D, Resp Inflammat & Autoimmun Innovat Med, Molndal, Sweden4 aut0 (Swepub:uu)mafri535 |
700 | 1 | a Hammarlund-Udenaes, Margaretau Uppsala universitet,Institutionen för farmaceutisk biovetenskap,Translational PKPD4 aut0 (Swepub:uu)marghamm |
710 | 2 | a Uppsala universitetb Institutionen för farmaceutisk biovetenskap4 org |
773 | 0 | t European Journal of Pharmaceutical Sciencesd : Elsevier BVg 92, s. 173-182q 92<173-182x 0928-0987x 1879-0720 |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-267596 |
856 | 4 8 | u https://doi.org/10.1016/j.ejps.2016.07.003 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Kopiera och spara länken för att återkomma till aktuell vy